Skip to main content

Top Left Menu

  • Careers
  • Media

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Aesthetics
    • Consumer Care
    • Prescription Medicine
    • Global presence
    • Executive Committee
    • Governance
    • Annual Review 2021
  • Skin Stories
  • Skin Science
  • Innovation
    • Skin Science by Galderma
    • Bringing innovation to life
    • Partnering
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • Our ESG roadmap
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • For society
    • Governance oversight
    • Funding request for education and support activities
  • Media
  • Careers

Galderma announces the launch of FACE by Galderma™ – a game-changing augmented reality solution helping healthcare professionals grow their activity and improve patient satisfaction

Press release

Galderma expands footprint with new Global Capability Center in Barcelona to support global growth

Press release

IMCAS 2023: Galderma to share latest data demonstrating high aesthetic improvement and patient satisfaction across its innovative portfolio

Press release

Galderma announces intention to expand manufacturing and innovation footprint in Asia-Pacific

Press release

Galderma debuts the Sensitive Skincare Faculty, a global expert group to improve understanding and management of sensitive skin

Press release

Galderma showcases its continued commitment to innovation in dermatology with new data to be presented at 2022 EADV congress

Press release

Galderma delivers strong H1 2022 results and continued innovation across its leading dermatology portfolio

Press release

Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis

Press release

Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet)

Press release

Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022

Press release

Pagination

  • Next page Next Page
Subscribe to Global release

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2023

Footer menu 2

  • Terms of use
  • Privacy
  • Cookie notice
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back